Our research is geared to understanding cancer, its aberrant behaviour and control, and to translate our discoveries for the benefit of cancer patients. We also study the pre-malignant state, so as to understand risk and how to prevent and treat cancer.
The Edinburgh CRUK Centre integrates the latest technologies and multi-disciplinary approaches, addressing fundamental questions and big challenges in cancer research.
We aim to provide an inspiring training environment for scientists and clinicians.
Have you, or someone you know been affected by Brain Cancer?
Join playwright Louise Page at the CRUK Edinburgh Centre (ECRC-IGMM) on Wed 12 Aug, 10am-12.
Louise Page is working with the CRUK Edinburgh Centre as she weaves together the experiences of patients, doctors & scientists. Louise has written for the Archers on BBC Radio 4, and is well known for raising awareness of patient experience, such as through plays like ‘Tissue’ at the Fringe 2015. We hope to bring a tapestry of real stories to the stage or radio revealing the complex journey of brain cancer diagnosis & research. The session will also be available to attend remotely through telephone or periscope. For Periscope please follow @CRUKEastScot on Twitter.
The event is free and refreshments will be provided.
For more information or to register for a free place email firstname.lastname@example.org or call 0131 651 8596.
MRC Molecular Pathology Node: Edinburgh-St Andrews Consortium for Molecular Pathology, Informatics and Genome Sciences - £2m
To support molecular pathology, the MRC and EPSRC have supported six nodes led by the universities of Edinburgh, Glasgow, Leicester, Manchester, Newcastle and Nottingham. Each node brings researchers, clinicians and industry together to develop molecular diagnostic tools, to enable stratification, in disease areas such as cancer, respiratory diseases, digestive disease, infections, rheumatoid arthritis, psoriasis and lupus.
The six nodes are collaborating with 20 industrial partners, including leading diagnostic and instrumentation companies and innovative technology and data SMEs.
Professor Sir John Savill, Chief Executive at the MRC, said: “These new tools are critical for selecting the right treatment for the right patient. Being able to precisely target a treatment means maximum benefit for the patient – they receive a treatment that works for them and with fewer unpleasant side-effects. But it also delivers economic benefit because money and time are not wasted on ineffective treatments.”
The Edinburgh-St Andrews Consortium will bring molecular diagnostics into mainstream medicine by use of modern genome technologies and information across a range of diseases. The consortium will integrate state-of-the-art genomic and epigenomic methods for diagnosis of acutely ill children and will develop ‘liquid biopsies’ for managing cancer through analysis of circulating tumour DNA. The node provides funding for a Masters by Research in Molecular Pathology which will provide full support for student(s) to undertake a one year Masters Course.
The Edinburgh Cancer Research UK Centre acknowledges the hard work of our PhD students and the contributions they make towards our Centre, the IGMM and to the scientific community.
Cancer Research UK (CRUK) organises a yearly meeting in London where all the PhD students funded by the charity are invited.
The meeting provided a series of workshops and career advice to help them with their PhD and beyond. The day also hosted talks from prominent researchers that recently acquired fellowships from CRUK’s prestigious funding schemes.
Students had an opportunity to network and those in their 3rd year presented their work during a poster session judged by the invited speakers. This year’s winner was Georgios Kanellos from the Edinburgh Cancer Research UK Centre.
Georgios Kanellos said: “Cancer Research UK provides funding to the best researchers based in the charity’s own leading Institutes and Centres. So one thing that is guaranteed is science in its highest levels. I am delighted to have been given the opportunity to present my work in such a competitive environment and won the best poster prize award. This re-assured that my research is on the right track and gave a boost to my confidence for my future career in cancer research.”
Kanellos’s work focuses on a family of proteins that have been found to be essential in brain and neuronal development, mainly by being involved in regulating cell motility. These proteins appear to be deregulated in many cancers and have been linked with the invasive and metastatic capacity of cancer cells in a variety of tumours. George’s novel research shows that there is more to their functions than just controlling cell movement, showing that some of the proteins are also essential for the maintenance of tissue homeostasis and cancer cell survival.
“Cells that lack these proteins lose control over their actin cytoskeleton, which in turn affects nuclear integrity, promotes DNA damage and results in cell death.”
The research opens a new window towards understanding the importance of this protein family for tissue homeostasis, cell viability and maintenance in cancer.
Congratulations to Professor Mike Dixon - Edinburgh Cancer Research Centre clinical researcher and a world-leading expert in treating breast cancer, who has recently been awarded Health Champion at Edinburgh Local Hero Awards. Based at the Western General Hospital, Prof Dixon has worked as a specialist surgeon for more than two decades. He also leads a research team dedicated to understanding why the most common form of breast cancer becomes resistant to drugs, which helps give sufferers the best chance of survival possible. Click here to read Edinburgh Evening News article about the award ceremony. To see Prof Dixon's profile on the ECRC website click here, and to learn more about his recent life saving research click here.